Anti-Coagulants - Southeast Asia

Southeast Asia

Highlights

In Southeast Asia, the Anti-Coagulants market is anticipated to witness a significant increase in revenue, with projections indicating that it will reach US$371.60m by 2024.
Furthermore, it is expected to exhibit a steady annual growth rate (CAGR 2024-2029) of 8.19%, leading to a market volume of US$550.70m by 2029.
When compared to other regions globally, it is worth noting that United States is anticipated to generate the highest revenue in the Anti-Coagulants market, projected to amount to US$16.74bn in 2024.
In Southeast Asia, the demand for anti-coagulants is on the rise due to an aging population and an increase in lifestyle-related diseases.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Coagulants market in Southeast Asia is experiencing significant growth due to several factors.

Customer preferences: Patients in Southeast Asia have a high prevalence of cardiovascular diseases, leading to a high demand for anticoagulants. Additionally, the aging population in the region has increased the need for anticoagulants as they are more prone to blood clots.

Trends in the market: The Anti-Coagulants market in Southeast Asia is witnessing a shift towards direct oral anticoagulants (DOACs) due to their ease of use and fewer side effects compared to traditional anticoagulants. DOACs are also more effective in preventing strokes in patients with atrial fibrillation.

Local special circumstances: One of the unique circumstances in Southeast Asia is the high prevalence of herbal medicines. Patients in the region often use traditional herbal medicines as an alternative to Western medicine. This has led to a need for education on the potential interactions between herbal medicines and anticoagulants.

Underlying macroeconomic factors: Southeast Asia is experiencing economic growth and an increase in healthcare expenditure. This has led to an increase in the availability and accessibility of anticoagulants in the region. Additionally, the region has a large population with a high burden of cardiovascular diseases, leading to a significant market for anticoagulants.In conclusion, the Anti-Coagulants market in Southeast Asia is developing due to the high prevalence of cardiovascular diseases, the aging population, and the shift towards DOACs. The unique circumstance of herbal medicine use in the region also needs to be considered. The underlying macroeconomic factors of economic growth and healthcare expenditure have also contributed to the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.